Table 4.

Comparison of EFS distributions for the M6620 plus cisplatin combination to single agent M6620 and single agent cisplatin

Xenograft	Cisplatin T-C (Days)	M6620 T-C (Days)	Combination T-C (Days)	P-value [combination vs. cisplatin]	P-value [combination vs. M6620]
BT-29	7.6	7.7	20.8	0.02	0.03
KT-10	81.0	−0.6	81.0	1	<0.01
KT-13	8.0	−0.1	9.2	0.31	<0.01
SK-NEP-1	80.9	3.3	80.9	1	<0.01
KT-12	8.5	1.4	8.0	0.28	<0.01
KT-5	28.7	0.5	74.0	<0.01	<0.01
Rh30R	5.4	−0.3	5.4	0.53	0.39
TC-71	3.4	−1.6	6.7	0.19	<0.01
EW5	24.4	−17.2	7.1	0.48	<0.01
EW8	−0.7	−1.4	−1.0	0.55	0.76
Rh18	8.8	1.9	6.7	0.77	<0.01
Rh30	6.1	−8.0	5.8	0.73	<0.01
Rh41	8.3	0.9	13.4	0.61	<0.01
BT-50	−8.5	−6.5	−4.5	0.82	0.79
GBM2	7.4	−0.8	4.3	0.08	<0.01
D645	2.9	−0.1	0.6	0.02	0.84
D456	3.8	1.7	4.3	0.18	<0.01
D212	6.3	−1.8	6.4	0.69	<0.01
NB-1691	3.3	4.4	5.3	0.65	0.13
NB-EBc1	0.7	3.3	6.1	<0.01	0.07
NB-1643	0.9	0.6	0.9	0.84	0.57
OS-2	4.6	−13.8	12.6	0.61	<0.01
OS-17	5.7	6.2	6.1	0.23	0.75
OS-9	−0.4	−0.9	29.6	<0.01	0.22